Advertisement
Advertisement
U.S. markets open in 9 hours 8 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BLUE Dec 2021 12.500 call(CONTR

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
10.000.00 (0.00%)
As of 09:49AM EST. Market open.
Advertisement
Full screen
Previous Close10.00
Open10.00
Bid5.40
Ask7.30
Strike12.50
Expire Date2021-12-17
Day's Range10.00 - 10.00
Contract RangeN/A
Volume3
Open Interest3
  • Benzinga

    Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA

    The FDA has accepted Bluebird bio Inc's (NASDAQ: BLUE) marketing application for betibeglogene autotemcel (beti-cel) for β-thalassemia. The agency has granted priority review for Beti-cel, gene therapy for β-thalassemia across all genotypes who require regular red blood cell transfusions. If approved, beti-cel will be the first one-time treatment that addresses the underlying genetic cause of disease—offering an alternative to regular RBC transfusions and iron chelation therapy. The agency has s

  • Business Wire

    bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions

    CAMBRIDGE, Mass., November 22, 2021--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for betibeglogene autotemcel (beti-cel) for priority review. Beti-cel is a potentially transformative gene therapy for adult, adolescent and pediatric patients with β-thalassemia across all genotypes who require regular red blood cell (RBC) transfusions. If approved, beti-cel will be the first one-time treatme

  • American City Business Journals

    After split, bluebird bio's new CEO looks to 'regain confidence'

    "Regaining confidence and credibility is something that I'm very focused on," bluebird bio CEO Andrew Obenshain told the Business Journal. "The only thing I can do in this circumstance is meet the deliverables I say I'm going to meet."

Advertisement
Advertisement